Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Nektar TherapeuticsNASDAQ: NKTR
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses turns positive
Q2 FY2026 other income / expenses was $2.04M, compared with -$5.55M a year earlier. Trailing-twelve-month other income / expenses was -$25.52M.
Context
- Other income / expenses amounted to 60.6% of revenue in FY2025, up 46.3 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near $2.04M or moves back toward the trailing-twelve-month quarterly average of -$6.38M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (33.44M) USD
- Year-over-year change
- -138.8%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.44M) | -138.8% |
| FY2024 | 2024-12-31 | (14M) | +89.9% |
| FY2023 | 2023-12-31 | (138.83M) | -11.3% |
| FY2022 | 2022-12-31 | (124.75M) | -61.6% |
| FY2021 | 2021-12-31 | (77.18M) | — |
Other Income / Expenses vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.6% is the 7th highest of 10, against a peer median of +6.3%.
- Other income / expenses amounts to 46.8% of revenue for NKTR, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.23M USD | +206.4% | +46.5% | 52.6% | |
| LTM Jun 2026 | $34M USD | +6.3% | +33.1% | 29.1% | |
| LTM Mar 2026 | $21.54M USD | -13.2% | +29.7% | 5.6% | |
| LTM Jun 2024 | $11.25M USD | — | -72.8% | 173.3% | |
| FY2025 | €4.25M EUR | +101.9% | — | 152.4% | |
| LTM Mar 2026 | $4.18M USD | -19.6% | +32.8% | 5.8% | |
| LTM Mar 2026 | $3.76M USD | +136.9% | — | — | |
| LTM Mar 2026 | -€2.64M EUR | -106.2% | — | 7.1% | |
| LTM Mar 2026 | -$2.91M USD | +59.5% | — | 6.2% | |
| LTM Mar 2026 | -$7.37M USD | -116.5% | — | 4.7% | |
| LTM Jun 2026 | -$25.52M USD | -16.6% | — | 46.8% | |
| Peer median (excluding NKTR) | — | +6.3% | +32.8% | 7.1% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 101.91M | 92.06M | 90.12M | 98.43M | 55.23M |
| Cost of Revenue | 24.9M | 21.64M | 36.64M | 30.69M | 0 |
| Gross Profit | 77.01M | 70.42M | 53.48M | 67.74M | 55.23M |
| Gross Margin | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% |
| Research & Development | 400.27M | 218.32M | 114.16M | 120.91M | 117.33M |
| Selling, General & Admin | 122.84M | 92.33M | 77.42M | 76.75M | 68.67M |
| Operating Expenses | 523.11M | 310.66M | 190.9M | 172.94M | 186M |
| Depreciation & Amortization | 14.15M | 12.2M | 7.82M | 4.39M | 1.03M |
| EBITDA | (461.82M) | (323.87M) | (243.11M) | (86.7M) | (137M) |
| EBITDA Margin | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
| Operating Income | (446.1M) | (240.24M) | (137.43M) | (105.2M) | (130.77M) |
| Operating Margin | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% |
| Interest Income | 2.73M | 6.78M | 19.01M | 14.5M | 10.44M |
| Interest Expense | 47.31M | 28.91M | 25.33M | 28.11M | 26.18M |
| Other Income / Expenses | (77.18M) | (124.75M) | (138.83M) | (14M) | (33.44M) |
| Income Before Tax | (523.28M) | (364.98M) | (276.26M) | (119.2M) | (164.21M) |
| Pre-Tax Margin | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% |
| Income Tax Expense | 557K | 3.22M | (200K) | (239K) | (138K) |
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Net Margin | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% |
| EPS (Basic) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| EPS (Diluted) | (42.90) | (29.51) | (21.79) | (8.68) | (9.73) |
| Weighted Avg Shares | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
| Weighted Avg Shares (Diluted) | 12.22M | 12.48M | 12.67M | 13.71M | 16.87M |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.